Wet Age Related Macular Degeneration

Wet AMD occurs when abnormal blood vessels grow under the retina and leak causing vision loss.

What is wet macular degeneration?

Wet macular degeneration occurs when abnormal blood vessels (known as choroidal neovascularization) grow under the macula. These new blood vessels may then bleed and leak fluid, causing the macula to bulge or lift up from its normally flat position, thus distorting or destroying central vision. It is called wet because of the fluid the leaks from the abnormal blood vessels. Patient with wet macular degeneration usually develop rapid vision loss over the course of weeks or months. Straight lines may look wavy because the macula is no longer smooth. Below is a discussion of various manifestations of wet AMD. Click the button to learn more about the treament of wet AMD

Treatment of Wet AMD

What is a Choroidal Neovascular membrane?

Choroidal neovascular membranes are new blood vessels that grow beneath the retina and disrupt vision. These blood vessels grow in an area called the choroid, the area between the retina and the sclera (the white part of your eye). The choroid supplies oxygen and nutrients to the eye. These blood vessel growths break through the barrier between the choroid and the retina. Although one would think that more blood vessels supplying nutrients to the eye would be good, it is not. The new blood vessels grow out with scarring. Also, they leak more than normal retinal blood vessels. Finally they can bleed and blood is very harmful to the retina. Rarely patient maintain good vision with choroidal neovascular membranes (about 10 or 20 percent). Most people lose central vision rapidly who develop choroidal neovascular membranes unless they are treated.

What is a Disciform Scar?

Untreated, a person with a choroidal neovascular membrane will usually develop a submacular scar like the one in the photo. The scars are white because the are composed mostly of fibroblasts. Subretinal scars cause degeneration of the overlying retina and loss of vision. The scars are circular or disc shaped and therefore are called disciform scars. They cause vision loss because they block the transport of nutrients from the supporting tissue under the retina (the retinal pigment epithelium) which is vital to the survival and function of the retina. Unfortunately, once the retina has been permanently damaged by a submacular scar it cannot be resurrected. Retinal tissue does not regenerate. It cannot be replaced. Research is being pursued all over the world trying to find a way to fix damaged retinas, but nothing, at the moment (January 2015) is close to being effective.

What is Subretinal Fluid?

A hallmark of wet AMD is subretinal fluid. This comes from leaking abnormal blood vessels under the macula. Their is not a firm attachment between the retina and the underlying retinal pigment epithelium. The retina is held in place against the underlying retinal pigment epithelium by a pump in the retinal pigment epithelium. This pump removes naturally occurring fluid in the subretinal space and keeps it dry. The leakage from a choroidal neovascular membrane overwhelms the natural pump in the retinal pigment epithelium and subretinal fluid accumulates. The subretinal fluid distorts the retina causing patients to see things as wavy instead of straight. It also decreases the supply of oxygen and nutrients to the retina and makes the vision blurry. Subretinal fluid is best dectected using optical coherence tomography. The photo shows a dark area under the retina where subretinal fluid has accumulated. The effect (or lack of effect) of treatments for wet macular degeneration is usually evaluated by monitoring the optical coherence tomography scan for subretinal fluid.

What is a Pigment Epithelial Detachment?

Most patients with wet AMD develop a retinal pigment epithelial detachment. The retinal pigment epithelium is a layer of cells under the retina that supports the retina. In the OCT image it is the bright white line closest to the bottom of the picture with RPE on top of it. (there are two lines, the line on the bottom is the RPE, the line on the top is the back of the retina). When fluid or lipid (fatty material) or blood vessels accumulates under the retinal pigment epithelium the retinal pigment epithelium is pushed up. The bump in the retinal pigment epithelium is called a pigment epithelial detachment. These are common in wet AMD. Treatment does not always cause the retinal pigment epithelial detachment to flatten. Vision can be excellent over a retinal pigment epithelial detachment. The distortion of the overlying retina will often cause distortion in the vision. Retinal pigment epithlial detachments do not compromise the ability of the retinal pigment epithelium to nurish the retina. Finally, you can develop a retinal pigment epithelial detachment without wet AMD. These retinal pigment epithelial detachments have lipid (fatty) material in them but no blood vessels. About 90 percent of retinal pigment epithelial detachments are associated with wet AMD and abnormal blood vessel growth.

What is a Polypoidal Choroidal Vasculopathy (PCV)?

Polypoidal choroidal vasculopathy is a subtype of wet AMD that is caused by a mature vascular complex under the retina. It is characterized by a branching vascular network with one or more polyps at the termini of the vessels. The branching vascular network and the polyp(s) are best seen with indocyanine green angiography. There is some evidence the polypoidal choroidal vasculaopathy (PCV) is less response to anti-VEGF injection therapy than other forms of wet AMD. In many cases photodynamic therapy is helpful in treating PCV.

What is a Submacular Hemorrhage (Blood)?

Submacular hemorrhage (blood) is one of the most feared complications of wet AMD. The blood is toxic to the overlying retina and causes immediate severe vision loss. The photo shows blood in a patient whose vision dropped from 20/30 immediately to 20/1600 (no longer able to see even the big letters on the visual acuity chart). Fortunately, submacular hemorrhage is rare and occurs in only about 1 percent of patient with wet AMD. Once there is a submacular hemorrhage, vision almost never returns to what it was before the bleed. Treatment of wet AMD helps reduce the amount of vision loss. Surgery for submacular hemorrhage is controversial and may not be helpful. Visual recovery in someone with a submacular hemorrhage is very very slow. It usually takes about 6 months for the blood to absorb and then another 6-12 months for the overlying retina to heal. Vision usually improves some as the blood absorbs but not much. Most patients recover enough vision to see the big letters on the visual acuity chart but not enough vision to read.

Wet Macular Degeneration NEWS

Below are current articles from a Google News Feed on Wet Macular Degeneration

  1. Treatment for Wet Age-Related Macular Degeneration Receives Biologics License Application Approval  Pharmacy Times
  2. Novartis Eyes Late 2019 Launch for Wet AMD Drug  biospace.com
  3. Months after Regeneron secured FDA approval for 12-week Eylea regimen, Novartis buys speedy US review for its rival  Endpoints News
  4. Novartis looks to favorable dosing regimen for edge in wet AMD  The Pharma Letter
  5. Novartis files potential blockbuster eye drug with FDA  pharmaphorum
  6. View full coverage on Google News
First patient dosed in Innovent wet AMD trial  Healio

Innovent Biologics has dosed the first patient in a phase 1 trial of IBI302, the company's wet age-related macular degeneration treatment candidate, according to ...

Novartis' BLA Acceptance Allows Entrance Into Large And Turbulent Wet AMD Market  Seeking Alpha

Novartis announced that the FDA had accepted its BLA for brolucizumab to treat patients with wet age-related macular degeneration. The company chose to use ...

Vitamins, new treatments offer hope for people with macular degeneration  nwitimes.com

Macular degeneration is the leading cause of vision loss, affecting more than 10 million Americans — more than cataracts and glaucoma combined.

What Is Age-Related Macular Degeneration?  Next Avenue

Age-related macular degeneration (AMD) causes deterioration of the macula, the part of the eye that provides sharp, clear, straight-ahead vision. As many Here ...

FDA Accepts BLA for Brolucizumab as Wet AMD Therapy  MD Magazine

The humanized single-chain antibody fragment could become the first of its kind approved for the common eye condition.

Age-related macular degeneration may be reduced by artificial intelligence  Health Europa

Action Against AMD have partnered with artificial intelligence company BenevolentAI to uncover the mysteries of age-related macular degeneration.

UPDATED: Adverum Bio offers a late notification about FDA hold on lead gene therapy for wet AMD  Endpoints News

The FDA has some questions for Adverum Biotechnologies about the CMC work related to their lead gene therapy for wet, age-related macular degeneration, ...

Drug for Leading Cause of Blindness Gets Priority Review  Managed Care magazine

The FDA has granted a priority review designation for RTH258 (Brolucizumab, Novartis) for the treatment of wet age-related macular degeneration (AMD).

VIDEO: Oral treatment shows good visual improvement in newly diagnosed wet AMD patients  Healio

FORT LAUDERDALE, Fla. — At the Retina World Congress, Michael W. Stewart, MD, professor and chairman of ophthalmology at the Mayo Clinic in ...

Novartis Announces FDA Filing Scceptance, Priority Review Of Brolucizumab For Patients With Wet AMD  PharmaLive

Novartis announces FDA filing acceptance and Priority Review of brolucizumab (RTH258) for patients with wet AMD. – By 2020, over 1.5 million people in the ...

Lutronic Vision Engages World Renowned Retina Expert for R:GEN™ Pilot AMD Clinical Study  Associated Press

Press release *content* from Globe Newswire. The AP news staff was not involved in its creation.

Experimental Drug Delivers One-two Punch to Vision Loss  R & D Magazine

Researchers have found that an experimental drug may be twice as good at fighting vision loss as previously thought.

Adverum Announces Clinical Hold, But It Should Not Hinder Its Gene Therapy Path  Seeking Alpha

Adverum announced that the FDA has placed a clinical hold on one of its gene therapy products known as ADVM-022 to treat patients with wet age-related ...

Anti-VEGF Agents better than no Anti-VEGF agents for AMD Patients  MD Magazine

Investigators from Johns Hopkins examined 16 RCTs to determine efficacy of three anti-VEGF agents for patients with neovascular age-related macular ...

EastEnders' actress June Brown losing her sight  BBC News

EastEnders veteran June Brown has said she can no longer recognise her friends as she deals with age-related macular degeneration at the age of 92.

Does an improved safety profile strengthen Allergan's case for a wet AMD challenge to Lucentis?  Endpoints News

Allergan has chalked up some flattering safety data for abicipar as it refines the eye drug's manufacturing processes in preparation of an impending BLA filing.

Biotech with a $2 Billion Market Cap has a $10 Billion Wet AMD Treatment in Development  The Wall Street Transcript

Gbola Amusa is Partner, Director of Research and Head of Healthcare Research of Chardan. Dr. Gbola Amusa joined Chardan at the end of 2014 to focus on ...

Eye Associates of New Mexico Patient Is First in State to Receive a Telescope Implant for Macular Degeneration after Previous Cataract Surgery  Associated Press

Press release *content* from Globe Newswire. The AP news staff was not involved in its creation.

Age-related macular degeneration: Study identifies genes for future therapies  Medical News Bulletin

Researchers study the role of epigenetic regulation of genes in the development of age-related macular degeneration that is the leading cause of blindness in ...

Wet Age-Related Macular Degeneration (AMD) Market Explores New Growth Opportunities  Market Research Gazette

The market is predominantly driven by the increase in prevalence of AMD, lack of availability of specific treatment, and surge in geriatric population, according to ...

Avastin for wet AMD: what will break the gridlock? - The BMJ  The BMJ

The ongoing battle between 12 clinical commissioning groups (CCGs) in the north of England and Bayer and Novartis over the legality of offering off-label ...

Alkahest Presents Positive Results from Phase 2a Open Label Study of AKST4290 in Treatment-Naïve neovascular AMD at Retina World Congress  PRNewswire

SAN CARLOS, Calif., March 25, 2019 /PRNewswire/ -- Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to ...

FDA accepts Novartis' application for brolucizumab for wet AMD  Seeking Alpha

Under priority review status, the FDA accepts Novartis' (NYSE:NVS) marketing application seeking approval for brolucizumab for the treatment of wet age-rel.

Novartis' speedy brolucizumab review tees up battle with Eylea, Lucentis  FiercePharma

Look out, Roche and Regeneron—Novartis eye candidate brolucizumab is on its way. Monday, the FDA said it had granted the wet age-related macular ...

What does Novartis' eye business envision without Alcon? Digital M&A, for one thing  FiercePharma

Now that Alcon is officially off on its own, what is Novartis and its remaining eye medicine business looking at next? Cutting-edge innovations, including gene ...

Answer to Degenerative Blindness Might Lie Inside Plants  Interesting Engineering

Scientists are on the way to developing a treatment for degenerative blindness using compounds from plants. The study shows that some plants can be used to ...

What Is the Difference Between Wet or Dry Macular Degeneration?  University of Michigan Health System News

Dry macular degeneration occurs when cells of the macula begin to thin and break down. It is characterized by drusen buildup and typically worsens over time.

Possible New Drug May Help Combat Vision Loss  Bel Marra Health

A new experimental drug may be able to combat vision loss. The study was conducted on lab-grown human cells and mice by Johns Hopkins researchers.

Experimental drug 'slows down macular degeneration'  Spectator.co.uk

An experimental drug may be twice as good at fighting vision loss as previously thought, according to new research by Johns Hopkins Medicine. The new…

Regenxbio (RGNX) Appoints Dr. Steve Pakola as CMO  StreetInsider.com

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here. REGENXBIO Inc. (Nasdaq: RGNX), a leading ...

Histogenics and Ocugen Enter into Definitive Merger Agreement to Create Nasdaq-Listed Clinical-Stage Company Developing Novel Ocular Gene Therapies and Biotherapeutics  Associated Press

Press release *content* from Globe Newswire. The AP news staff was not involved in its creation.

Tracon shares trounced as phase III angiosarcoma trial terminated  BioWorld Online

BioWorld Online is the news *service* of record for the biotechnology industry and is updated every business morning. BioWorld Online will keep you up to date ...

Macular Degeneration Treatment Market: Application of anti-VEGFs to treat Wet AMD Soars  openPR

Age-related macular degeneration is one of the main causes of irreversible, severe vision impairment in developed countries. The incidence, prevalence and ...

Allergan's AMD Drug Lowers Inflammation in Phase III Study  Zacks.com

Allergan's (AGN) MAPLE study evaluating a 12-week dose of abicipar pegol demonstrates decreased intraocular inflammation in nAMD patients.

Wet Age-Related Macular Degeneration Market Provides Information on the Historical and Current Market Size and the Future Potential of the Market  openPR

The global wet age-related macular degeneration (AMD) market, estimated at $6.9 billion in 2018, is projected to reach $10.4 billion by 2024, registering a ...

What you need to know about wet macular degeneration  Medical Xpress

Millions of people deal with age-related macular degeneration as they get older, but many don't understand the difference between types of the condition or ...

Outlook Therapeutics Announces FDA Acceptance of IND for ONS-5010  GlobeNewswire

Enrollment of U.S. patients in the ONS-5010-002 Phase 3 clinical trial expected to be initiated in calendar Q2 2019.

Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives  Benzinga

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 15) ...

Fewer Injections With New Wet Macular Degeneration Therapies  Medscape

New treatments in development — including gene therapy — will likely mean fewer injections for patients with neovascular age-related macular degeneration, ...

Stealth BioTherapeutics Announces Dosing Of First Patient In Phase 2 Study Of Elamipretide For The Treatment Of Dry AMD  P&T Community

BOSTON, March 28, 2019 /PRNewswire/ -- Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, ...

Syncona joins Gyroscope, Orbit to create eye gene therapy player  pharmaphorum

UK biotech Gyroscope Therapeutics is to merge with Orbit Biomedical of the US to create a specialist in gene therapies for eye diseases. The combined ...

TRACON Pharmaceuticals Announces Termination of Phase 3 TAPPAS Trial Based on the Recommendation of the Independent Data Monitoring Committee  GlobeNewswire

Company to Host Investor Conference Call Today at 8:30 a.m. EDT / 5:30 a.m..

7 Tips to Stop Macular Degeneration  Healthline

Macular degeneration is one of the leading causes of blindness in the United States. Here's how to keep your vision safe while enjoying the sun this spring ...

Take steps to prevent vision loss from macular degeneration  Buffalo News

By Judith Whitehead – Contributing Writer Age-related macular degeneration is the leading cause of blindness among older Americans but treatments have ...

Adverum Biotechnologies Appoints Ophthalmology Industry Veteran Aaron Osborne, MBBS MRCOphth, as Chief Medical Officer  Associated Press

Press release *content* from Globe Newswire. The AP news staff was not involved in its creation.

Trial will be first in US of Nobel-winning stem cell technique  STAT

Curing diabetes with stem cells? Everyone knew that would be hard. Parkinson's disease? Harder. Alzheimer's? Probably impossible. But age-related macular ...

Biosimilars Market Size to Reach $26.7 Billion by 2024: P&S Intelligence  GlobeNewswire

NEW YORK, April 15, 2019 (GLOBE NEWSWIRE) -- According to the market research report published by P&S Intelligence, biosimilars market is expected to ...

Age-Related Macular Degeneration: 5 Things to Know  Medscape

A guide to the latest on this chronic disease, from emerging treatments to the risk factors to be on the lookout for.

Kodiak Sciences Announces Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights  BioSpace

Published: Mar 28, 2019. PALO ALTO, Calif., March 28, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company ...

First patient dosed in Ocular Therapeutix wet AMD trial  Healio

The first patient has been dosed in a phase 1 clinical trial of OTX-TKI for patients with wet age-related macular degeneration, according to a press release from ...

Market Insights of Wet Macular Degeneration Market by Major Competitor, Size, Subdivision, Market Dynamics Forces  Top 360 News

Wet Macular Degeneration Market report covers the disease overview, definition, classification, symptoms, ethology, pathophysiology and diagnostic methods.

Wet Age-Related Macular Degeneration Market to Reach $10.4 Billion by 2024: P&S Intelligence  GlobeNewswire

NEW YORK, March 11, 2019 (GLOBE NEWSWIRE) -- According to the market research report published by P&S Intelligence, global wet age-related macular ...

5 questions: Breakthroughs in treatment for a common cause of vision loss among U.S. seniors  Philly.com

The standard treatment has been regular injections to the eyeball. So, not surprisingly, an active area of research has focused on finding alternatives, including ...

TRACON Pharmaceuticals Announces TRC105, TRC253 and TRC102 Data Presentations at Upcoming AACR Annual Meeting  GlobeNewswire

SAN DIEGO, March 27, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the ...

VIDEO: Notal Vision pursues home-based OCT for wet AMD monitoring  Healio

CHICAGO — At the Ophthalmology Innovation Summit at AAO, Quinton Oswald, CEO of Notal Vision, discusses the company's pursuit of an OCT home ...

Seeing clearly: Know your risk for macular degeneration  Baylor College of Medicine News

More than 60 million Americans are estimated to be at high risk for vision loss. However, according to the CDC, only half of those at risk have visited an eye ...

7 Healthy Habits to Help Prevent Macular Degeneration  University of Michigan Health System News

AMD affects the eyesight of millions. A Michigan Medicine specialist offers easy ways to help slow or prevent the disease.

Aged-related macular degeneration is incurable but preventable  New Jersey 101.5 FM Radio

Aged-related macular degeneration is the top cause of blindness in people age 50 and older.

Tie2 activation promotes choriocapillary regeneration for alleviating neovascular age-related macular degeneration  Science Advances

Choriocapillary loss is a major cause of neovascular age-related macular degeneration (NV-AMD). Although vascular endothelial growth factor (VEGF) blockade ...

RGX-314 Gene Therapy for Wet AMD Well Tolerated at 24 Weeks  MD Magazine

After a single dose of RGX gene therapy, the mean change in BCVA was +8 letters in cohort 3 and the average number of injections over the course of 6 months ...

These 3 Value Stocks Are Absurdly Cheap Right Now - Motley Fool  The Motley Fool

Good bargains are hard to find in today's market. Here are a few overlooked stocks for you to capitalize on.

Revolutionary eye drops to treat age-related macular degeneration  Drug Target Review

Revolutionary eye drops to treat age-related macular degeneration - developing an eye drop that could revolutionise treatment for AMD.

Implantable Ranibizumab Port for Wet AMD Lasts Up to 15 Months  MD Magazine

In a phase 2 study, a long-acting, implantable delivery system for ranibizumab allowed patients with wet age-related macular degeneration to go up to 15 ...

Macular Degeneration Patient Visual Hallucinations Associated with Retina  MD Magazine

The effects of Charles Bonnet Syndrome have been fairly documented, yet its pathology has been minimally assessed.

Novel anti-VEGF for wet AMD meets safety, tolerability endpoint  Healio

WAIKOLOA, Hawaii — Sunitinib, a novel intravitreal anti-VEGF delivered via a biodegradable depot for extended treatment of neovascular age-related macular ...

Human Trials Could Begin for Macular Degeneration Stem Cell Therapy  MD Magazine

FDA trial approval would make this trial the first ever to test a stem cell-based therapy derived from induced pluripotent stem cells for treating any disease.

Two phase 3 trials to investigate faricimab for wet AMD  Healio

Roche and Genentech are initiating two phase 3 global trials to investigate the bispecific molecule faricimab for the treatment of wet age-related macular ...

Roche's Faricimab Shows Long-Term Durability in Macular Degeneration  BioSpace

Roche announced positive data from its Phase II STAIRWAY clinical trial. The trial evaluated the extended durability of faricimab (RG7716) in the treatment of ...

How to spot age-related macular degeneration  The Guardian

Every day in the UK, nearly 200 people develop a condition that can lead to visual impairment or even blindness. How do you identify the symptoms and what's ...

Be aware of age-related macular degeneration  thebellvillestar.com

COLUMBUS — Age-related macular degeneration (AMD), is a leading cause of vision loss for Americans age 50 and older. The eye disease causes damage to.

Fresh insights into genes and macular degeneration could open new treatment pathways  FierceBiotech

NIH researchers have pinpointed 6 genomic regions that are closely associated with the development of age-related macular degeneration. (Pixabay).

Wills Eye Hospital releases new implant to help macular degeneration  KYW Newsradio 1060

PHILADELPHIA (KYW Newsradio) — There may soon be a way to preserve your vision with a lot less hassle.

Opthea Confirms Final Patient Enrolment in Phase 2b Wet AMD Clinical Trial  Associated Press

Press release *content* from Globe Newswire. The AP news staff was not involved in its creation.

Dr. Kumar-Singh Presents: Anti-Complement Gene Therapy for Dry and Wet AMD: Research Lecture Series  New England College of Optometry

Feb. 19, 2019, 5:00 - 6:00 PM | New England College of Optometry, LH-2. Please join Dr. Kumar-Singh, Tufts University, as he presents, “Anti-Complement Gene ...

Implant Poised to Transform Macular Degeneration Treatment  Medscape

A system that delivers ranibizumab without injections could be a turning point for patients with neovascular age-related macular degeneration, results from the ...

Macular degeneration treatment market size worth around US $11.4 billion by 2026: Acumen Research and Consulting  GlobeNewswire

LOS ANGELES, March 16, 2019 (GLOBE NEWSWIRE) -- The global macular degeneration treatment market size is anticipated to value USD 11.4 billion by ...

7 Macular Degeneration Risk Factors You Can Control—and 4 You Can't  Reader's Digest

Your chances of getting this top cause of vision loss in people age 60 and older—depends on both your genetics and your lifestyle.

Age-Related Macular Degeneration Drug Combo Scrapped Despite Safe Profile  Specialty Pharmacy Times

Ophthotech Corp. said it won't move forward with further clinical trials of its complement factor C5 inhibitor for the treatment of wet age-related macular ...

Stem Cell Therapy Patch for Macular Degeneration Sees the Light of Day  Genetic Engineering & Biotechnology News

If approved, the first ever clinical trail to test a stem cell-based therapy may provide a cure for age-related macular degeneration.

FDA Approves Aflibercept sBLA for Wet Age-related Macular Degeneration  MD Magazine

A modified 12-week dosing schedule is now available for physicians administering the vascular endothelial growth factor (VEGF) inhibitor to patients with wet ...

VIDEO: Gene therapy advances in inherited retinal disease, AMD, optogenetics  Healio

WAIKOLOA, Hawaii ― Elias Reichel, MD, discusses the latest advances in gene therapy for inherited retinal diseases, age related macular degeneration and ...

New Stairway Study Data Shows Potential for Extended Durability with Faricimab in Wet Age-Related Macular Degeneration (AMD)  Associated Press

Press release *content* from BusinessWire. The AP news staff was not involved in its creation.

CCGs win right to offer patients Avastin for wet AMD  The BMJ

BMJ 2018; 362 doi: https://doi.org/10.1136/bmj.k4035 (Published 24 September 2018) Cite this as: BMJ 2018;362:k4035. Article · Related *content* · Metrics ...

Patients with Concurrent Cataracts, Wet AMD Safe to Undergo Cataract Surgery  MD Magazine

Most patients, whether or not they had preoperative fluid, saw improved BCVA post-surgery, and there were no significant differences in central subfield ...

Regenxbio completes dosing in phase 1 trial of gene therapy for wet AMD  Healio

Dosing is complete in a phase 1 clinical trial of RGX-314, a gene therapy treatment for wet age-related macular degeneration, according to a press release from ...

Roche and Genentech take global macular degeneration step  PharmaTimes

Roche and Genentech have initiated two large global Phase III clinical trials testing the potential of faricimab in wet age-related macular degeneration. - News ...

Breakthrough in identifying new genes in age-related macular degeneration, the leading cause of blindness  Medical Xpress

Fight for Sight funded research published this week in Clinical Epigenetics, has identified new genes linked to the development of age-related macular ...

Computers Found to Equal Humans in Diagnosing Age-Related Macular Degeneration  MD Magazine

Computers can do as well as clinicians in diagnosing age-related macular degeneration, say investigators who have developed tools based on artificial ...

AMD Monitoring Comes Home: The Promise of Remote Tech  Medscape

Age-related macular degeneration (AMD) is the leading cause of severe vision loss in older Americans. AMD is a degenerative disease that affects the macula, ...

Gene therapy first to 'halt' most common cause of blindness  BBC News

A woman from Oxford has become the first person in the world to have gene therapy to try to halt the most common form of blindness in the Western world.

Drug Pipeline for Macular Degeneration in Focus at AAO  Medscape

Updates from phase 3 trials of VEGF inhibitors for neovascular age-related macular degeneration, and a novel genetic treatment, will be highlighted at the ...

Surgeons perform first gene therapy procedure aimed at stopping AMD-related blindness  Healio

Researchers have completed the first gene therapy procedure aimed at stopping age-related macular degeneration.The operation was performed at John ...

Tiny eye device could make big difference for millions with blinding disease  Philly.com

Wills Eye Hospital has helped test an implantable delivery system for a widely used medication for age-related macular degeneration.

Hope for new treatments buoys macular degeneration patients  The Boston Globe

Scientists are experimenting with dozens of new treatments, including about 20 in clinical trials, to combat an eye disease that afflicts more than 9 million ...

Researchers are one step closer to developing eye drops to treat age-related macular degeneration  Medical Xpress

Scientists at the University of Birmingham are one step closer to developing an eye drop that could revolutionise treatment for age-related macular degeneration ...

Bayer and Novartis appeal ruling that Avastin for wet AMD is lawful  The BMJ

BMJ 2018; 363 doi: https://doi.org/10.1136/bmj.k4586 (Published 30 October 2018) Cite this as: BMJ 2018;363:k4586. Article · Related *content* · Metrics ...

Metformin for Macular Degeneration  Healthline

The popular diabetes medication, metformin, may soon be used not just to regulate blood sugar but to protect against a common form of blindness, called ...

Eyeing Improvement: Fine-Tuning Anti-VEGF for Macular Degeneration  MD Magazine

Anti-VEGF injection therapy is the proven choice of care for AMD and DME. Still, concerns about dosing, costs, and convenience persist into 2019.

Reducing Treatment Burden in Neovascular Age-related Macular Degeneration: What's Now? What's Next?  Healio

Education Lab | Neovascular, or “wet” age-related macular degeneration (nAMD) imposes a high burden on patients and eye care providers alike, as optimal ...

» Load more

What about Resources?

Dr. Pautler's Blog
American Academy of Ophthalmology
National Institutes of Health
  • ARMD
    NIH's SeniorHealth website covers the topic of Age-Related Macular Degeneration
National Eye Institute
American Foundation for the Blind - Senior Site
  • Macular Degeneration
    Basic information about AMD and low vision; includes a self-test using an Amsler Grid
Journal of the American Medical Association (JAMA)
LightHouse International
  • Macular Degeneration
    Provides a general overview of the basics of AMD, and a simulation showing a scene as it might be viewed by a person with AMD
Prevent Blindness America